Kairos Pharma, Ltd.
KAPA
$0.785
-$0.026-3.21%
AMEX
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
3/28/2025
-
Newsfile Corp. - News Releases
11/19/2024
-
Globe Newswire
10/22/2024
-
Globe Newswire
10/9/2024
-
Globe Newswire
9/24/2024
-
Globe Newswire
9/17/2024
-
Globe Newswire
9/16/2024
-
Globe Newswire
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
--
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Tuesday, April 15, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of Aug 11 and 15 (est)
Price History
Beta
--
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
--
2-Year Total Return
--
3-Year Total Return
--
5-Year Total Return
--
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
--
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
310-948-2356
Address
2355 Westwood Boulevard
Los Angeles, CA 90064
Los Angeles, CA 90064
Country
Year Founded
Business Description
Sector
Kairos Pharma, Ltd., a clinical-stage biopharmaceutical company, develops therapeutics for cancer patients. Its therapeutics include antibodies and small molecules for the treatment of prostate...
more